Show simple item record

dc.contributor.authorErdoğan, Cem
dc.contributor.authorÇiftçi, Bahadır
dc.contributor.authorKızılaslan, Deniz
dc.contributor.authorEkinci, Mürsel
dc.contributor.authorİpteç, Gülşen
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorKaraaslan, Pelin
dc.date.accessioned2020-09-29T11:02:22Z
dc.date.available2020-09-29T11:02:22Z
dc.date.issued2020en_US
dc.identifier.citationErdoğan, C., Çiftçi, B., Kızılaslan, D., Ekinci, M., İpteç, G., Gemici, A. ... Karaaslan, P. (2020). High-dose intravenous immunoglobulin therapy for novel coronavirus disease 2019: A brief report of two cases. Ain-Shams Journal of Anesthesiology, 12(1). https://dx.doi.org/10.1186/s42077-020-00089-4en_US
dc.identifier.issn1687-7934
dc.identifier.issn2090-925X
dc.identifier.urihttps://dx.doi.org/10.1186/s42077-020-00089-4
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5886
dc.description.abstractTo the Editor,Novel coronavirus disease 2019 (2019-nCoV) is a global pandemic which threatens all over the world. Thefirst cases were seen in Wuhan, China, in December2019 (Guo et al. 2020; Chen et al. 2020). It has spreadrapidly, and now, there are more than 2.3 million reported cases and 160,000 deaths worldwide. 2019-nCoVmay cause multi-system infections especially respiratoryinfections such as severe acute respiratory syndrome(SARS) and Middle East respiratory syndrome (MERS)(Guo et al. 2020; Chen et al. 2020; Sanders et al. 2020).In some cases, infections may be mild (only cough orfever, etc.); however, in some cases, infections may be severe (acute respiratory failure with diffuse pneumonia).In severe cases, there is an exaggerated immune response with low peripheral lymphocyte levels and highcytokine levels. This mechanism of pathogenesis may beresponsible for the multiple organ failures (Cao et al.2019; Lin et al. 2020). In this early stage of the 2019-nCoV, the infection may be treated successfully withimmunomodulation (Cao et al. 2019). So, the immunomodulation options like intravenous immunoglobulinshould be kept in mind. The intravenous immunoglobulin (IVIg) has been used as a replacement therapy insome immunodeficiency syndromes (Ballow 2008; DeRanieri 2017). IVIg plays an immunomodulatory andanti-inflammatory role in such cases like 2019-nCoV(Cao et al. 2019; Lin et al. 2020).en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectCoronavirusen_US
dc.subjectImmunoglobulin Therapyen_US
dc.subjectIntravenousen_US
dc.titleHigh-dose intravenous immunoglobulin therapy for novel coronavirus disease 2019: A brief report of two casesen_US
dc.typeletteren_US
dc.relation.ispartofAin-Shams Journal of Anesthesiologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Anesteziyoloji ve Reanimasyon Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-5715-8138en_US
dc.authorid0000-0002-3245-6614en_US
dc.authorid0000-0001-6587-8103en_US
dc.authorid0000-0002-5580-5960en_US
dc.authorid0000-0002-5273-1871en_US
dc.identifier.volume12en_US
dc.identifier.issue1en_US
dc.relation.publicationcategoryDiğeren_US
dc.identifier.doi10.1186/s42077-020-00089-4en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess